Timeframe: Up to 1 year after the last participant is randomized
Progression-Free Survival (PFS)
Timeframe: Up to 5 years after the last participant is randomized
Secondary (27)
Very Good Partial Response (VGPR) or Better Rate
Overall Survival (OS)
Change in Disease Symptoms as Assessed by the European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire (EORTC QLQ)-Multiple Myeloma Module 20 (MY20)
Overall Response Rate (ORR)
Complete Response (CR) Rate
Show 22 moreShow less
Time to Response (TTR)
Time to Best Response (TTBR)
Duration of Response (DOR)
Progression-Free Survival (PFS)
Progression-Free Survival 2 (PFS2)
Overall MRD-Negative Complete Response Rate
Overall MRD-Negative Rate
Sustained MRD-Negative CR Rate
Percentage of Participants With Adverse Events (AEs)
Tolerability as Assessed by the Incidence of Dose Interruptions, Dose Reductions, Dose Intensity, and Treatment Discontinuation
Number of Participants With Presence, Frequency of Occurrence, Severity, and/or Degree of Interference With Daily Function of Shortness of Breath, Cough, Heart Palpitations, Rash, Dizziness, and Nausea Assessed NCI PRO-CTCAE
Change From Baseline in Shortness of Breath, Cough, Heart Palpitations, Rash, Dizziness, and Nausea Assessed by the National Cancer Institute Patient Reported Outcomes Common Terminology Criteria for Adverse Events (NCI PRO-CTCAE)
Change From Cycle 1 Day 8 in Treatment-Related Side Effect Bother as Assessed by the Functional Assessment of Cancer Therapy-General, General Population 5 (FACTG GP5)
Change from Baseline in the Global Health Status/Quality of Life (GHS/QoL) of the EORTC QLQ-Core 30 (C30)
Time to Confirmed Deterioration in Disease Symptoms, as Assessed by EORTC QLQ-MY20
Time to Confirmed Deterioration in GHS/QoL as Assessed by the EORTC QLQ-C30
Change From Baseline in Fatigue as Assessed by the EORTC QLQ-C30
Time to Confirmed Deterioration in Fatigue as Assessed by the EORTC QLQ-C30
Percentage of Participants Experiencing Clinically Meaningful Improvement in Disease Symptoms as Assessed by the EORTC QLQ-MY20
Percentage of Participants Experiencing Clinically Meaningful Improvement in GHS/QoL as Assessed by the EORTC QLQ-C30
Percentage of Participants Experiencing Clinically Meaningful Improvement in Fatigue as Assessed by the EORTC QLQ-C30
Percentage of Participants with Anti-Drug Antibodies (ADAs) to Cevostamab at Baseline and with ADAs to Cevostamab During the Study
Cevostamab will be administered intravenously on a 21-day cycle in cycle 1 and on a 28-day cycle from cycle 2 onwards.
Pomalidomide will be administered orally (PO) on a 28-day cycle from cycle 2 onwards.
Dexamethasone will be administered as a premedication prior to cevostamab.
Standard of Care (SOC)Active comparator
Participants will receive investigator's choice of one SOC regimen.
China 14, United States 14, Japan 13, Germany 8, France 7, Spain 7, Italy 6, Poland 6, South Korea 6, Denmark 4, Israel 4, United Kingdom 4, Czechia 3, Greece 3, Australia 2, Brazil 2, Canada 1, Puerto Rico 1